Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The lessons learned from the clinical application of epidermal growth factor receptor tyrosine kinase inhibitors provide important insights for lung cancer therapies. What approaches might circumvent the rapid acquisition of resistance and increase the efficacy of targeted therapies in lung cancer and other epithelial cancers?
The Salvador–Warts–Hippo (SWH) pathway is involved in tissue growth control in Drosophila melanogaster. There is increasing evidence that deregulation of this conserved pathway occurs in human tumours. What insights do the studies in Drosophila provide for human carcinogenesis?
Cancer patients often experience cognitive changes after chemotherapy (sometimes called “chemo brain”). What are some possible molecular mechanisms for this detrimental side effect of cancer therapy?
Transient protein–protein interactions occur in many cellular processes that are implicated in cancerous growth, such as cell-cycle transitions mediated by the cell division cycle 25 phosphatases. What are the issues that are encountered when considering these transient interactions as drug targets?
As we have evolved, we have aquired several evolutionary traits that might increase our susceptibility to cancer development. Mel Greaves outlines the benefits of a Darwinian view of cancer biology, cause and treatment.
